State of New Jersey Common Pension Fund D raised its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 21.1% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 230,000 shares of the life sciences company’s stock after acquiring an additional 40,000 shares during the quarter. State of New Jersey Common Pension Fund D owned approximately 0.16% of Illumina worth $71,459,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors have also bought and sold shares of the business. Robeco Institutional Asset Management B.V. grew its holdings in shares of Illumina by 56.3% during the first quarter. Robeco Institutional Asset Management B.V. now owns 94,698 shares of the life sciences company’s stock worth $29,422,000 after buying an additional 34,122 shares in the last quarter. Park Avenue Securities LLC purchased a new stake in shares of Illumina during the first quarter worth about $229,000. Avitas Wealth Management LLC purchased a new stake in shares of Illumina during the first quarter worth about $897,000. Rhumbline Advisers grew its holdings in shares of Illumina by 5.7% during the first quarter. Rhumbline Advisers now owns 271,730 shares of the life sciences company’s stock worth $84,424,000 after buying an additional 14,658 shares in the last quarter. Finally, Parallel Advisors LLC grew its holdings in shares of Illumina by 20.3% during the first quarter. Parallel Advisors LLC now owns 6,565 shares of the life sciences company’s stock worth $2,040,000 after buying an additional 1,109 shares in the last quarter. Hedge funds and other institutional investors own 89.75% of the company’s stock.
A number of equities research analysts have recently commented on ILMN shares. BidaskClub downgraded shares of Illumina from a “buy” rating to a “hold” rating in a report on Tuesday, April 30th. Bank of America reiterated a “buy” rating and set a $355.00 price target on shares of Illumina in a report on Wednesday, January 30th. Canaccord Genuity reiterated a “buy” rating and set a $350.00 price target (down from $360.00) on shares of Illumina in a report on Friday, April 26th. Zacks Investment Research downgraded shares of Illumina from a “buy” rating to a “hold” rating in a report on Wednesday, January 30th. Finally, Leerink Swann raised shares of Illumina to an “outperform” rating and decreased their target price for the stock from $380.00 to $365.00 in a research report on Wednesday, January 30th. Three analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $353.58.
Shares of ILMN traded down $4.72 during mid-day trading on Wednesday, hitting $308.28. The company had a trading volume of 648,900 shares, compared to its average volume of 969,140. The company has a debt-to-equity ratio of 0.27, a quick ratio of 3.33 and a current ratio of 3.66. Illumina, Inc. has a 1-year low of $261.61 and a 1-year high of $372.61. The stock has a market capitalization of $45.93 billion, a PE ratio of 53.90, a P/E/G ratio of 2.18 and a beta of 1.15.
Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, April 25th. The life sciences company reported $1.60 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.34 by $0.26. The business had revenue of $846.00 million for the quarter, compared to analysts’ expectations of $838.70 million. Illumina had a net margin of 25.06% and a return on equity of 23.49%. The company’s quarterly revenue was up 8.2% on a year-over-year basis. During the same period last year, the company earned $1.45 earnings per share. As a group, sell-side analysts expect that Illumina, Inc. will post 6.68 earnings per share for the current fiscal year.
In other Illumina news, Director Robert S. Epstein sold 1,000 shares of Illumina stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $313.93, for a total transaction of $313,930.00. Following the transaction, the director now directly owns 4,256 shares of the company’s stock, valued at $1,336,086.08. The sale was disclosed in a filing with the SEC, which is available at this link. Also, SVP Charles Dadswell sold 1,220 shares of Illumina stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $313.93, for a total transaction of $382,994.60. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 50,031 shares of company stock worth $15,572,547. 0.38% of the stock is currently owned by corporate insiders.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Recommended Story: What is a stock buyback?
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.